Daiichi Sankyo Co., Ltd. (4568)

Overview

Daiichi Sankyo Company, Limited is a globally recognized pharmaceutical company known for its extensive portfolio of medical products and treatments. With its headquarters in Tokyo, Japan, and operations spanning across the globe, Daiichi Sankyo has carved out a leading position in the pharmaceutical industry since its foundation in 1899. The company's dedication to innovation and healthcare improvement is evident through its wide range of pharmaceutical products, which cater to various medical conditions and diseases. In addition, Daiichi Sankyo has entered into significant partnerships, such as a development and commercialization agreement with Merck, focusing on advancing antibody drug conjugate (ADC) candidates, demonstrating its commitment to pioneering in the field of medical research and drug development.

Products and Services

• Enhertu: A HER2 directed antibody drug conjugate designed for precision-targeted cancer therapy.
• Turalio: A CSP-1R inhibitor serving as a treatment option for certain patients, showing Daiichi Sankyo's focus on innovative cancer therapies.
• Vanflyta: A FLT3 inhibitor used for treating adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia, emphasizing the company's commitment to addressing hard-to-treat cancers.
• Ferric Carboxymaltose Injection & Injectafer: These treatments are focused on combating iron deficiency anaemia, illustrating the company's efforts in addressing common but impactful health issues.
• Olmesartan Medoxomil: An antihypertensive agent, showcasing Daiichi Sankyo's contribution to cardiovascular health management.
• NILEMDO & Nustendi: Oral treatments designed to help in lowering cholesterol, part of the company's portfolio of cardiovascular health products.
• Canalia: A medication for treating type 2 diabetes mellitus, reflecting the company's attention to the global diabetes epidemic.
• Emgalty: Aimed at the treatment of migraine attacks, offering relief for those suffering from this debilitating condition.
• Pralia: An anti-osteoporosis medication that also inhibits the progression of bone erosion associated with rheumatoid arthritis, demonstrating Daiichi Sankyo's focus on bone health.
• Ranmark: Targeted at the treatment of bone complications caused by bone metastasis from tumors, again highlighting the company’s investment in oncology.
• Tarlige: Focused on treating pain, underscoring the company’s commitment to improving quality of life for patients with chronic conditions.
• Tenelia: Another treatment option for Type 2 diabetes mellitus, further representing Daiichi Sankyo’s dedication to combatting the diabetes health crisis.
• Venofer: Aimed at treating iron deficiency anemia, adding to the company's portfolio of treatments for anemia.
• Vimpat: An anti-epileptic agent, contributing to the company’s efforts in addressing neurological conditions.
• Vaccines: Including inoculations for influenza, measles/rubella, and mumps, showcasing Daiichi Sankyo’s role in public health through preventative measures.